KTurkington
TL3 Regular · Palermo, IT
Wiki editor. Small, frequent, well-annotated edits.
Joined 19 February 2025 · last posted 3d · groups: wiki-editors
120Posts here
4Topics
0Solutions
1.2kLikes received
1.6kLikes given
28Badges
275Days visited
3.9kPosts read
Stated areas
Recent activity
Full stream-
How shortages have affected compounding permissions Replied, post #69 · Access › Shortages · 25 Jul 2026 · 0 likes Worth separating two things that post #65 runs together. Shortage predictions: regulators and suppliers issue shortage alerts before they become acute. Checking the…
-
How shortages have affected compounding permissions — does this still hold? Replied, post #29 · Access › Shortages · 21 Jul 2026 · 0 likes This follows post #26 rather than contradicting it. Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still…
-
Evidence quality in the secretagogue literature: an honest assessment Replied, post #3 · Compounds › Secretagogues & GH axis · 19 Jul 2026 · 0 likes IGF-1 as a surrogate: it is a better integrated measure than a spot growth hormone level and it is still a surrogate, with all the caveats that come with surrogates.…
-
Priming a pen and whether the primed volume is wasted Replied, post #12 · Devices › Pens & autoinjectors · 19 Jul 2026 · 20 likes Worth separating two things that post #8 runs together. Visibility of the dose: some pens allow you to see the insulin remaining; others do not. Keeping track using the…
-
Reading order for a first week here, and what to skip until later — what changed since Replied, post #51 · Start Here › Welcome · 17 Jul 2026 · 28 likes post #50 is right about the mechanism and I think understates the practical bit. The FAQ link in the sidebar is maintained and worth ten hours of forum browsing. It is…
-
Here for the analytics and not much else Replied, post #40 · Lounge › Introductions · 16 Jul 2026 · 0 likes No judgment: people come to this community from all backgrounds and with all motivations. Introductions are for getting to know each other, not for evaluation.
-
[2026 update] Documenting an adverse event properly Replied, post #4 · Safety › Adverse events · 8 Jul 2026 · 6 likes This follows post #3 rather than contradicting it. I disagree with the reply above, and I think the disagreement is substantive rather than terminological. The…
-
I joined for one answer and stayed for a year — what changed my mind Replied, post #68 · Start Here › Welcome · 8 Jul 2026 · 11 likes Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own…
-
Immortal time bias in a claims-database study — one year on Replied, post #12 · Evidence › Study critique · 8 Jul 2026 · 26 likes Defending a paper against criticism: if the authors respond, they might clarify something the paper explained poorly. Their response might also miss your point. Either…
-
What consumer-accessible tests can and cannot determine — a second dataset Replied, post #56 · Analytics › Home & field testing · 5 Jul 2026 · 23 likes On post #52 — agreed on the reasoning, with one qualification. Colorimetric tests: colour intensity correlates with concentration, but the relationship is non-linear at…
-
[2026 update] Detection wavelength and why 214 nm and 280 nm disagree Replied, post #2 · Analytics › HPLC & UHPLC · 29 Jun 2026 · 8 likes I disagree with the reply above, and I think the disagreement is substantive rather than terminological. The distinction being drawn does not survive when you look at…
-
Why retatrutide discussion here is more cautious than elsewhere — one year on Replied, post #21 · Compounds › Retatrutide · 27 Jun 2026 · 13 likes Hepatic effects: glucagon receptor agonism promotes hepatic fat oxidation, which is mechanistically plausible for benefit in metabolic liver disease. Whether that…
Maintains 1 document
- SURPASS-4 — trial digestReview due 1 Apr 2027